Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NVRO's continued technological innovations and business diversification plans raise optimism about the stock.

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX.

Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second...

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were stron...

Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System.

NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.

NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal -...

Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.